美股市场个股详情

PEPG PepGen

添加自选
  • 14.200
  • -0.290-2.00%
收盘价 05/03 16:00 (美东)
  • 14.200
  • 0.0000.00%
盘后 16:01 (美东)
4.60亿总市值-4303市盈率TTM
全部分时
  • 5日
  • 日K
  • 周K
  • 月K
  • 季K
  • 年K

资金分布

单位: --

资金流向

实时

暂无数据

新闻

评论

    $PepGen(PEPG.US)$ PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
    4
    Mary Beth DeLena's addition to PepGen's executive team is viewed positively, her vast legal and compliance experience is anticipated to significantly contribute to PepGen's aim of providing next-gen oligonucleotide therapies for severe neuromuscular and neurological diseases.

    PepGen Inc. dosed their first patient for the treatment of Duchenne muscular dystrophy (DMD)

    $PepGen(PEPG.US)$
    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose (MAD) clinical trial evaluating PGN-EDO51 for the ...

    Will be watching for data to come

    $PepGen(PEPG.US)$ PepGen Announced First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
    Benzinga· 5 mins ago

    Update! Watching!

    $PepGen(PEPG.US)$ promising data from their 5mg/Kg dose level cohort, which is expected to be shared in mid-2024. This data suggests a high dystrophin expression, which is a strong indicator of PGN-EDO51’s effectiveness. In a head-to-head comparison with SRP-5051, PGN-EDO51 showed a 13-fold increase in exon skipping.  Additionally, PepGen’s PGN-EDODM1 has shown promising early results, with significant correction of mis-splicing and myotonia after a single dose, and a tolerabili...
阅读更多

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议
美股
综合热度
股票代码
最新价
涨跌幅